Corticosteroid (CS) therapy is used widely in the treatment of a range of pathologies, but can delay production of myelin, the insulating sheath around central nervous system nerve fibers. The cellular targets of CS action are not fully understood, i.e. 'direct' action on cells involved in myelin genesis [oligodendrocytes and their progenitors the oligodendrocyte precursor cells (OPCs)] versus 'indirect' action on other neural cells. We evaluated the effects of the widely used CS dexamethasone (DEX) on purified OPCs and oligodendrocytes, employing complementary histological and transcriptional analyses.
Introduction
Corticosteroid (CS) therapy is currently used widely for the treatment of a range of pathologies, but can delay myelin genesis during development and repair (remyelination) in major white matter tracts of the central nervous system (CNS) including the optic nerve and corpus callosum. [1] [2] [3] [4] [5] [6] [7] Notably, high and multiple CS doses are frequently used during periods of developmental myelination, 8, 9 and to treat conditions involving myelin injury/repair such as Multiple Sclerosis and spinal cord injury. 10, 11 The cellular mechanisms underpinning the reported CS induced defects in myelin genesis are largely unknown, but observations that myelination delays occur without accompanying axon loss 2, 5 indicate that such effects may be primarily underpinned by glial responses to CS.
Myelination involves a sequential process: initially, proliferative and migratory precursors called oligodendrocyte precursor cells (OPCs) populate the CNS 12 and receive signals to generate oligodendrocytes. Astrocytes are important mediators of myelin genesis, by influencing OPC migration, proliferation and differentiation into oligodendrocytes; 13 the latter engage in complex, intercellular cross-talk with axons to generate functional myelin. 14 Oligodendrocytes continue to generate myelin sheaths well into adulthood (about the fifth decade) in the temporal and parietal lobes, with perturbations to this process being linked to cognitive decline in Alzheimer's disease. 15 Following myelin injury, remyelination broadly recapitulates developmental myelination, and critically depends on a timed orchestration of cellular and molecular events in lesions. 16 Myelin genesis in the normal and diseased CNS is therefore a complex multifactorial process, and studies aiming to establish the cellular targets of CS action during myelinogenesis yield contradictory information. 17 Evidence for direct effects on OPCs includes CS treatment of CG4 cells (an OPC line) 18 and adrenalectomized rats, 19 where OPC proliferation was inhibited.
Further, CS have pro-differentiation effects on myelinogenic cells, 20, 21 but in demyelination models CS can delay 22 or enhance 23 remyelination. These confounding responses may relate to the immunomodulatory effects of CS on microglia; the latter remove myelin debris (inhibitory to myelin genesis) and secrete stimulatory/inhibitory cytokines that can impact oligodendrocyte development. 24 However, CS treatment of astrocytes can also down-regulate oligodendroglial differentiation factors. 25 While neurons engage in cross-talk with oligodendroglial cells during myelination, one study has reported limited CS effects in striatal neurons, suggesting that at least some neurons are not direct targets of CS action. 26 Such observations suggest that CS may impact myelination through indirect effects mediated by nonmyelinogenic glial cell intermediaries, but rigorous evaluation of direct effects of CS on oligodendroglia is lacking. There is heavy reliance in the field on histological observations in cultures, but the constituent cell types are often poorly characterized. 27, 28 In terms of drug action, CS are lipid-soluble, readily entering cells where they bind to appropriate cytosolic ligand-activated receptors, with nuclear translocation of complexes and action on hormone response elements to regulate the associated genes. 29 In this context, the critical question of whether oligodendrocyte lineage cells express the glucocorticoid receptor (GR) is also not fully resolved, with two studies yielding contradictory results. 19, 30 The widespread clinical use of CS in conjunction with the critical roles of myelin in neuroprotection and regulation of electrical conductivity 16 highlight the need to resolve such conflicting information by defining the mechanisms underpinning aberrant myelinogenesis. To address this issue, and specifically, to evaluate if CS exert direct effects on oligodendroglial cells, we have employed a two-pronged methodological approach comprising histological analyses complemented with parallel transcriptional analyses (as CS effects are mediated by transcriptional regulation). We have employed isolated purified cultures, and short time frames for the studies, to evaluate direct cellular actions of CS and the potential primary/early targets of drug action respectively. We consider this approach necessary to provide comprehensive insights into the mechanisms by which CS therapy may impact myelination.
Results and Discussion
To the best of our knowledge, this is the first study to employ a dual methodological approach (that provides independent and corroborative readouts of CS effects at the morphological and molecular levels) in order to investigate the mechanisms by which this major class of anti-inflammatory drugs may impact myelin genesis. The inclusion of independent transcriptional analysis of DEX treated cultures, in conjunction with histological assays, provides an unbiased approach unhindered by prior expectation of CS effects on neural cells. Further, the use of isolated, purified glial cultures in these experiments allows for examination of direct actions of CS which cannot be evaluated within the context of the multicellular lesion environment in vivo. 3 High purity OPC, astrocyte and microglial cultures were generated as judged by staining for cell specific markers; values were: 96.4 ± 0.5% A2B5 + (n = 6) and 96.9 ± 1.2% NG2 + for OPCs (n = 3); 97.8 ± To monitor the effects of DEX on oligodendrocyte differentiation, OPC cultures (propagated in OPC-MM for 24 h) were switched to Sato differentiation medium and allowed to differentiate +/-DEX for up to 7
days. Complex process-bearing oligodendrocytes were found in both control and DEX treated oligodendrocyte cultures (Figure 2a-b) . No differences were observed between groups in the total number of nuclei or the percentage of pyknotic nuclei per microscopic field (Figure 2c-d) . Further, using our morphological scoring criteria, no CS effects were discernible on oligodendrocyte maturation in terms of the extent of process/membrane elaboration ( Figure 2g ). Therefore, DEX treatment did not affect the survival, proliferation, antigenic profiles or morphologies (including extent of differentiation) of oligodendrocyte lineage cells. (Figure 3a) . DEX treatment dramatically reduced cell densities with many cells showing a rounded appearance (Figure 3b-c) confirming that the CS preparations used were physiologically active, and the spectrophotometrically confirmed doses (see Methods) were appropriate for eliciting cellular responses. No significant differences were noted in microglial response to 1 and 100 µM DEX, presumably due to saturating concentrations of DEX employed. In this context, the dissociation constant (Kd) of GR with DEX is unknown for microglia, but is reported to be 3.5 -6.0 nM in multicellular cultures derived from rat brain. [31] [32] This is greatly exceeded by the lowest DEX dose tested (1 µM), and as DEX readily diffuses across the cell membrane, 33 this supports the concept of receptor saturation. Further, it
should be noted that biological responses to DEX in microglia 34 and other cell types [35] [36] [37] have been shown to display similar plateau effects. 
The absence of CS effects on oligodendrocyte lineage cells cannot be attributed to the absence of GR expression
The lack of an overt oligodendroglial response to CS treatment could be explained by an absence of the necessary receptor (GR) expression. Earlier studies report that oligodendroglial lineage cells express GR mRNA but evidence for GR expression in rat OPCs/oligodendrocytes has not been definitive. Although several studies report GR (mRNA or protein) expression in 'glial cells', often poorly characterized cultures 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 are employed in the experiments, leaving doubt regarding cell specific receptor expression and related CS effects. For example, Vielkind et al. 28 show GR expression in "tentatively identified" OPCs in mixed glial cultures, without OPC-specific counterstaining (some of these cells were GFAP + , suggesting that they are 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 the was also reported to be negatively regulated by glucocorticoids in neural progenitor cells. 44 Together, these observations underscore the validity/robustness of the microarray procedures utilized here. With respect to the microglial arrays, an unexpected finding was the identification of the transcription factor Olig1 as a DEX responsive gene, given its role as a master regulator of myelination, with expression reported in oligodendroglia and radial glia. 45, 46 Nevertheless, immunocytochemical approaches unequivocally demonstrated (i) Olig1 expression in cultured microglia, and (ii) up-regulation of protein expression by DEX treatment, further validating the sensitivity of the microarray system used here. The implications of this finding remain to be established, but do question the prevailing view that Olig1 expression in the CNS is restricted to oligodendrocyte lineage cells. 47 Consequently, the finding that the various cell types exhibit differing transcriptional responses to DEX (as shown here for the first time with CNS glia) is not without precedent. However, elucidation of the factors accounting for the inter-cellular differences -and limited glucocorticoid sensitivity of oligodendroglia, in particular -will require extensive further study. For example, whilst all glial cell types express the GR, information is lacking regarding the complement of GR isoforms expressed in each cell type. This is important because (i) diverse GR subtypes can be generated from the Nr3c1 gene locus (by alternative splicing coupled with the usage of alternative translation initiation sites), each subtype being further subject to multiple post-translational modifications (including phosphorylation, sumoylation, acetylation and ubiquitination), and; (ii) different protein isoforms can exhibit distinct transactivation/transrepression patterns of gene regulation. [47] [48] [49] Other factors influencing glucocorticoid action and which may differ between glial cell types include: GR chaperones/co-chaperones, transcriptional co-regulators and chromatin remodelling complexes; 47 transcription factors such as AP-1, NF-KB and STATs that participate in proteinprotein interaction with -and are modulated by -the GR; 47-49 the lncRNA GAS5 which acts as a decoy GRE to riborepress the GR; 50 and chromatin architecture. 51 CS are undoubtedly highly effective immunosuppressive agents that assist recovery in a range of pathologies. However, we consider that elucidation of the mechanisms of adverse effects of CS based immunotherapies is essential given the intimate relationship between myelination and axonal function/survival. For example, axons produce aberrant branches without the inhibitory effects of myelin. 52 The ordered arrangement of ion channels at the nodes of Ranvier (and therefore conductive properties of axons) also critically depends on correct myelination. 53 Oligodendrocytes are considered to be essential to long-term axonal integrity, potentially through trophic support mechanisms and axon-glia metabolic coupling mechanisms 54, 55 leading to a widely held view that axon-myelin interactions have an important neuroprotective role (and by extension impact disease progression when perturbed). 16 Consequently, CSinduced delays in myelination are of significant clinical importance when considering treatment of a range 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 of paediatric and adult pathologies. Our findings demonstrate that OL lineage cells show limited responses to CS and are therefore not likely to constitute the direct cellular targets of CS action in the CNS. This is a somewhat unexpected finding, given that both OPCs and oligodendrocytes are key players in the process of myelin genesis.
Central numbers indicate bp values of ladders. Fluorescence micrographs showing GR expression (H300 and BuGR2 antibodies) in lectin + microglia (b), GFAP + (c) and morphologically-identified astrocytes (c, inset), NG2 + OPCs (d) and MBP + oligodendrocytes (e). OL = oligodendrocyte.
However, the exact mechanisms by which microglia impact myelin production in vivo are not fully resolved.
Our pathway analyses do not indicate specific mechanisms by which microglial gene expression changes may directly impact myelin genesis, however more complex secondary effects may account for CS-induced myelin perturbations in vivo. During regeneration, impaired remyelination following microglial suppression is likely due to impaired myelin debris clearance. 56 Microglial roles in developmental myelination are less clear, however at least one study suggests that myelin synthesis can be stimulated by microglial cells, 57 through unknown secretory mechanisms. Further, it is established that microglia secrete several soluble mediators including those with key roles in the development of the oligodendroglial lineage, such as IGF-
58,59
The release of such mediators is the critical first step towards successful myelin regeneration, and it is feasible that similar mechanisms may be operational during developmental myelination, 56 and therefore perturbed by immunosuppressive therapies. We also cannot exclude the possibility that CS effects on myelin production may simply be related to a decrease in microglial numbers, as reported previously. In vivo DEX treatment has been shown to elicit a decrease in microglial numbers, this effect being dependent on both the dose employed 60 and the duration of treatment. 61 However, systematic correlative analyses of CS-induced microglial depletion and the progression of developmental myelination have not been conducted so far.
Microglia remove supernumerary neurons during development, but it is not clear whether they perform the same role for supernumerary oligodendroglial cells (which are known to be reduced by up to 50% during development). Depleted numbers of microglia, and/or microglial dysfunction could also impair removal of dead cells and regulation of glial population numbers, essential to establishing normal neuron:glia ratios and interactions during development. 62 In light of these points, the following transcriptional changes in our study may be of relevance. Analysis of the combination of all transcriptional changes on cellular function using the Ingenuity Pathway analysis tool showed (i) DEX-treatment resulted in altered expression of genes relating to 'cell movement' (including 'migration of microglia'), therefore CS-treated microglia may demonstrate an impaired ability to migrate 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 can potentially offer evidence for an indirect mechanism of CS effects on myelin genesis via a microglial/astrocytic cell intermediary. This detailed understanding can provide information relevant to the development of novel therapeutic agents/immunotherapies that limit adverse effects of CS, along with refinements to the timing and dose of existing CS therapy. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60
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Materials and methods
The care and use of animals was in accordance with the Animals (Scientific Procedures) Act of 1986 (United Kingdom) with approval by the local ethics committee.
Reagents: Tissue culture materials were from Fisher Scientific (UK). Recombinant human platelet-derived growth factor (PDGF-AA) and basic fibroblast growth factor (FGF2) were from Peprotech (UK).
Dexamethasone ( bovine serum albumin, 50 U/ml penicillin, 50 µg/ml streptomycin, 10 ng/ml PDGF-AA, and 10 ng/ml FGF2). Finally, after an additional shake (200 rpm, 18 h) to deplete residual OPCs, adherent astrocytes were trypsinized and plated at 4 x 10 4 cells/cm 2 in D10. To deplete microglia from OPC and astrocyte fractions, cells were transferred to non-tissue-culture grade petri dishes (to which microglia readily attach) and after 30 min the unattached cells were collected. To establish oligodendrocyte cultures, OPC cultures were switched to Sato differentiation medium [DMEM supplemented with 2 mM glutaMAX-I, 1 mM sodium pyruvate, 1x
N2 supplement (5 µg/ml insulin; 20 nM progesterone; 100 µM putrescine; 30 nM selenium; 100 µg/ml transferrin), 30 nM thyroxine, 30 nM triiodothyronine, 50 U/ml penicillin, and 50 µg/ml streptomycin]. All cultures were incubated at 37°C in 5% CO 2 /95% humidified air. Cells were plated on poly-D-lysine (PDL) coated 6-well plates for microarray/RNA studies, or PDL-coated chamber slides or coverslips in 24-well plates for histological studies.
DEX treatment of cultures:
DEX is frequently employed in clinical practice, 8, 11 particularly for the treatment of respiratory distress syndrome, 9 reduction of cerebral oedema associated with intracranial neoplasms, 67 and following acute spinal cord injury. 10 This drug was therefore selected for use in the experimental studies, and is reported to act almost exclusively on the GR. 68 Table 2 for antibody/marker details
Histological analyses
Immunocytochemistry: Cells were fixed with 4% paraformaldehyde in phosphate buffered saline (PBS)
[room temperature (RT); 30 min] and washed in PBS. Table 2 summarizes the antibodies used to detect specific cell types and the immunostaining protocols. Cells were blocked (RT; 30 min), incubated overnight with primary antibody in blocking solution (4°C; simultaneous antibodies for double-staining), washed, blocked, incubated with the appropriate FITC-or Cy3-conjugated secondary antibody in blocking solution
(1:200; RT; 2 h; simultaneous antibodies for double-staining), washed and mounted with the nuclear stain DAPI. As both H300 and GFAP require anti-rabbit secondary antibody, BuGR2 was used with GFAP to double-stain astrocytes. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 indicated by fragmented, intensely stained nuclei, as a measure of toxicity. For oligodendrocyte cultures, MBP + cells were assigned a morphological score to semi-quantitatively assess extent of differentiation/maturation as follows: (1) few or no processes, (2) processed but displaying some bipolarity, (3) multiple processes with loss of bipolarity (displaying radial symmetry), (4) highly-processed and (5) dense and elaborate/flattened processes. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 GR: fwd: 5'GAG CAG AGA ATG TCT CTA CCC; rev: 5'GAC GAT GGC TTT TCC TAG CTC. GAPDH: fwd: 5'ACC ACA GTC CAT GCC ATC AC; rev: 5'TCC ACC ACC CTG TTG CTG TA.
Microarray analysis: For each cell type, RNA samples from four cultures were dispatched to Source Bioscience UK Ltd. (Nottingham, UK) for processing and hybridisation. RNA integrity was determined using the Bioanalyzer (Agilent, USA) and the three pairs of RNA samples (DEX treated and vehicle only control samples from the same culture) with the highest quality per condition were selected for microarray analysis. 750 ng of processed cRNA was hybridized to Illumina RatRef-12 bead chips. Differentially expressed genes were identified using limma package of R. 77 Data was normalized using the neqc function of the limma package found to be robust for Beadarray analysis. 78 Beads with quality scores (detection probability) < 95% in any sample were removed, resulting in 15,498 genes analyzed. Significantly differentially-expressed genes were identified using a modified t-test with Benjamini-Hochberg test to control false discovery rate (FDR) for multiple testing. Genes were considered as differentially-expressed if corrected p values were < 0.05 and log2 fold change values were ≥ |1|. Enrichment and Pathway analysis was conducted using the MetaCore™ platform, with all genes reported here having an enrichment FDR corrected p value < 0.01 and a minimum of two genes in an enriched category. One transcriptionally-altered gene (Olig1) was selected in order to validate the microarray findings by double-immunostaining microglia for both lectin and Olig1, using OPCs (NG2 staining) and oligodendrocytes (MBP staining) as positive controls as Olig1 expression is considered to be restricted to oligodendrocyte lineage cells.
38
Statistical analysis: Other than for the array analysis described above, data were analyzed using Prism statistical analysis software (GraphPad, USA). All data are expressed as mean ± SEM. The number of experiments (n) refers to the number of mixed glial cultures from which isolated cultures were derived, with each primary culture being established from a different rat litter. For CS effects on oligodendroglia and microglia, data were analyzed by one-way ANOVA with Bonferroni's multiple comparison post-tests for post-hoc analysis. Optical density measurements of Olig1 expression were averaged for each culture/condition, normalized then analyzed by a paired t-test . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
